Hebei Weimiao Biology Co., LTD 1
Location
  • Home
  • lidocaine hydrochloride cas 73-78-9

פבר . 13, 2025 00:16 Back to list

lidocaine hydrochloride cas 73-78-9



Rilmazafone hydrochloride, identified by the CAS number 85815-37-8, has garnered attention in the pharmaceutical arena due to its unique characteristics and potential applications. This compound, originating from Japan, is primarily utilized in medical settings for its anxiety-relieving effects and is gradually being explored globally for diverse therapeutic purposes.

china cas 85815-37-8 rilmazafone hydrochloride

Rilmazafone hydrochloride acts as a prodrug, meaning it transforms into an active metabolite in the body to produce its pharmacological effects. This transformation process attributes to its popularity as it minimizes potential side effects during the transition. Upon ingestion, rilmazafone is metabolized into benzodiazepine receptor agonists, which promote sedation, induce sleep, and alleviate anxiety, akin to traditional benzodiazepines, but with a potentially reduced risk profile. Clinicians value rilmazafone for its efficacy in managing anxiety and insomnia, especially in populations sensitive to conventional benzodiazepines. Its chemical structure allows it to act differently on the central nervous system, which may result in fewer negative effects such as dependence and withdrawal symptoms, problems commonly associated with long-term benzodiazepine usage.

china cas 85815-37-8 rilmazafone hydrochloride

Despite its promising benefits, rilmazafone hydrochloride is not yet widely available internationally, largely due to regulatory hurdles and the need for comprehensive clinical trials in various demographic groups. This has not diminished interest, as ongoing international research, including studies out of China, aim to evaluate its full clinical potential and safety profile. Scientists are invested in determining optimal dosages, administration methods, and additional therapeutic uses, which could expand rilmazafone’s application to other areas such as treating panic disorders and epileptic seizures. The chemistry behind rilmazafone hydrochloride's metabolism underscores its favorable pharmacokinetics. After oral administration, it is swiftly absorbed and metabolically converted, predominantly by liver enzymes, ensuring quick therapeutic action. Its shorter half-life compared to other sedatives means that the drug is eliminated more rapidly from the body, reducing the risk of accumulation and adverse reactions.china cas 85815-37-8 rilmazafone hydrochloride
From an expertise standpoint, successful application of rilmazafone in clinical settings requires profound understanding of its pharmacodynamics and patient-specific factors such as age, liver function, and concurrent medication use. Healthcare providers should approach prescribing rilmazafone with caution, ensuring thorough patient evaluation to tailor treatment that maximizes benefit while minimizing risks. Rilmazafone's reputation as a reliable anxiolytic and hypnotic contributes significantly to its authoritativeness in the field. Supported by decades of clinical use in Japan, its therapeutic efficacy is well-documented, adding to its credibility. Ongoing studies conducted under stringent research protocols further bolster its trustworthiness, promising future global adoption as regulatory bodies gain confidence in its safety and efficacy. For those in the pharmaceutical industry, investing in rilmazafone hydrochloride represents an opportunity to meet growing demands for safer, effective sedatives and anxiolytics. Companies are encouraged to engage in collaborative research efforts, potentially with Chinese institutions, to address regulatory requirements and expand its reach worldwide. In summary, rilmazafone hydrochloride exemplifies a compound of significant potential in modern medicine, balancing efficacy and safety. Its journey from a lesser-known drug to a prospective staple in anxiety and sleep disorder treatment highlights the importance of integrating scientific research with clinical application. As new data emerges, rilmazafone is poised to reshape therapeutic options available to clinicians, setting precedent in the pharmaceutical landscape.
Share
Next：

Latest news

If you are interested in our products, you can choose to leave your information here, and we will be in touch with you shortly.


Hit enter to search or ESC to close
he_ILHebrew
en_USEnglish afAfrikaans sqAlbanian amAmharic arArabic hyArmenian azAzerbaijani euBasque belBelarusian bn_BDBengali bs_BABosnian bg_BGBulgarian caCatalan cebCebuano zh_CNChina zh_TWChina (Taiwan) coCorsican hrCroatian cs_CZCzech da_DKDanish nl_NLDutch eoEsperanto etEstonian fiFinnish fr_FRFrench fyFrisian gl_ESGalician ka_GEGeorgian de_DEGerman elGreek guGujarati htHaitian Creole haHausa hawHawaiian hi_INHindi hmnMiao hu_HUHungarian is_ISIcelandic igIgbo id_IDIndonesian gaIrish it_ITItalian jaJapanese jvJavanese knKannada kkKazakh kmKhmer rwRwandese ko_KRKorean ckbKurdish kyKyrgyz loLao laLatin lvLatvian lt_LTLithuanian lbLuxembourgish mk_MKMacedonian mgMalgashi ms_MYMalay ml_INMalayalam mtMaltese miMaori mrMarathi mnMongolian my_MMMyanmar ne_NPNepali nb_NONorwegian nyNorwegian orOccitan psPashto fa_IRPersian pl_PLPolish pt_PTPortuguese pa_INPunjabi ro_RORomanian ru_RURussian smSamoan gdScottish Gaelic sr_RSSerbian stSesotho snShona sdSindhi si_LKSinhala sk_SKSlovak sl_SISlovenian soSomali es_ESSpanish suSundanese swSwahili sv_SESwedish tlTagalog tgTajik ta_INTamil tt_RUTatar teTelugu thThai tr_TRTurkish tkTurkmen ukUkrainian urUrdu ug_CNUighur uz_UZUzbek viVietnamese cyWelsh xhBantu yiYiddish yoYoruba zuZulu he_ILHebrew